Hospitalization costs for congenital syphilis in the state of Ceará / Custo das internações hospitalares por sífilis congênita no Estado do Ceará

Abstract Objectives: this study aimed to describe direct medical-hospital costs of hospitalizations for Congenital Syphilis (CS) in children under one year of age, users of the public health network in the state of Ceará, Brazil, from 2012 to 2017. Methods: this is a cross-sectional study that used the DATASUS Hospital Information System database, built from the information registered in the Inpatient Hospital Authorizations (IHA), organized in a Microsoft Office Excel 2010 spreadsheet and analyzed in SPSS, version 23. Results: there were 4,085 hospitalizations registered for CS (16.6% of total hospital admissions for infectious and parasitic diseases) at a cost of US$ 927,726.84, representing an annual average of US$ 234.73 per child. A slight decrease in approved IHA for infectious and parasitic diseases (5.5%) was verified when compared with CS, which increased by 36.4%> over the evaluated years. Conclusion: high treatment costs for CS in the state of Ceará were identified, a situation that could be avoided if pregnant women with syphilis were diagnosed and treated during prenatal care.

Resumo Objetivos: descrever os custos diretos médico-hospitalares das internações hospitalares por Sífilis Congênita (SC) em crianças menores de um ano usuárias da rede pública de saúde do Estado do Ceará, no período de 2012 a 2017. Metodos: estudo transversal cuja coleta de dados aconteceu no banco de dados do Sistema de Informações Hospitalares do Datasus, a partir das informações das Autorizações de Internação Hospitalar (AIH). Os dados foram digitados em uma planilha no Microsoft Office Excel (versão 2010) e analisados no SPSS, versão 23. Resultados: foram registradas 4.085 internações hospitalares por SC (16,6% do total de internações por doenças infecciosas e parasitárias), perfazendo um custo total de $ 927. 726,84 dólares e média anual para cada criança de $234, 73dólares. Observou-se um discreto decréscimo das AIH aprovadas para doenças infecciosas e parasitárias (5,5%) quando comparadas com SC, que apresentou um acréscimo de 36,4%o ao longo dos anos avaliados. Conclusão: identificou-se custo elevado com o tratamento da SC no estado do Ceará, situação que poderia ser evitada se as gestantes com sífilis fossem diagnosticadas e tratadas durante a assistência pré-natal.

Clinical characteristics and outcomes for paediatric patients admitted with congenital or acquired syphilis: a population-based cohort study.

OBJECTIVES: Paediatric congenital and acquired syphilis cases have been increasing since 2012 in the USA. Potential differences in associated hospitalisation trends and healthcare utilisation between the two syphilis entities have not yet been assessed. We sought to compare these entities and describe their clinical characteristics, distribution and impact in the USA. METHODS: We conducted a population-based cohort study using the 2016 Kids' Inpatient Database (KID) to identify and characterise syphilis-associated hospitalisations among paediatric patients (age 0-21 years) in the USA during the year of 2016. Length of stay and hospitalisation costs for patients with congenital and acquired syphilis were compared in multivariable models. RESULTS: A total of 1226 hospitalisations with the diagnosis of syphilis were identified. Of these patients, 958 had congenital syphilis and 268 were acquired cases. The mean cost of care for congenital syphilis was $23 644 (SD=1727), while the treatment of a patient with acquired syphilis on average cost $10 749 (SD=1966). Mean length of stay was 8 days greater and mean total costs were $12 895 (US dollars) higher in the congenital syphilis cohort compared with the acquired syphilis cohort. In congenital syphilis, there were greater frequency of cases in the Southern and Western regions of the USA (p<0.001). CONCLUSION: Congenital syphilis was associated with greater healthcare-related expenditure than acquired syphilis in paediatric patients. In addition to improving patient outcomes, congenital syphilis prevention efforts may significantly reduce healthcare utilisation burden and cost.

Repeat Screening for Syphilis in the Third Trimester of Pregnancy: A Cost-Effectiveness Analysis.

OBJECTIVE: To estimate the cost-effectiveness of screening all women during the first and third trimesters compared with screening just once during pregnancy. METHODS: We used a theoretical cohort of 3.9 million women in the United States to model syphilis screening approaches in pregnancy, particularly comparing one-time screening with repeat third-trimester screening. Outcomes of syphilis infection included in the model were congenital syphilis, intrauterine fetal demise, neonatal death, and total quality-adjusted life-years (QALYs). Probabilities, utilities, and costs were obtained from the literature, and a cost-effectiveness threshold was set at $100,000 per QALY. A societal perspective was assumed. RESULTS: Our model demonstrated that repeat screening in the third trimester for syphilis in pregnancy will result in fewer maternal and neonatal adverse outcomes and higher QALYs when compared with screening once in the first trimester. Specifically, we demonstrated that repeat screening results in 41 fewer neonates with evidence of congenital syphilis, 73 fewer cases of intrauterine fetal demise, 27 fewer neonatal and infant deaths, in addition to a cost savings of $52 million and 4,000 additional QALYs. CONCLUSION: Using our baseline assumptions, our data support that in pregnancy, repeat screening for syphilis is superior to single screening during the first trimester and is both cost-effective and results in improvement in maternal and neonatal outcomes. When screening policies are being created for pregnant women, the cost-effectiveness of repeat screening for syphilis should be considered.

The cost and cost-effectiveness of scaling up screening and treatment of syphilis in pregnancy: a model.

BACKGROUND: Syphilis in pregnancy imposes a significant global health and economic burden. More than half of cases result in serious adverse events, including infant mortality and infection. The annual global burden from mother-to-child transmission (MTCT) of syphilis is estimated at 3.6 million disability-adjusted life years (DALYs) and $309 million in medical costs. Syphilis screening and treatment is simple, effective, and affordable, yet, worldwide, most pregnant women do not receive these services. We assessed cost-effectiveness of scaling-up syphilis screening and treatment in existing antenatal care (ANC) programs in various programmatic, epidemiologic, and economic contexts. METHODS AND FINDINGS: We modeled the cost, health impact, and cost-effectiveness of expanded syphilis screening and treatment in ANC, compared to current services, for 1,000,000 pregnancies per year over four years. We defined eight generic country scenarios by systematically varying three factors: current maternal syphilis testing and treatment coverage, syphilis prevalence in pregnant women, and the cost of healthcare. We calculated program and net costs, DALYs averted, and net costs per DALY averted over four years in each scenario. Program costs are estimated at $4,142,287 - $8,235,796 per million pregnant women (2010 USD). Net costs, adjusted for averted medical care and current services, range from net savings of $12,261,250 to net costs of $1,736,807. The program averts an estimated 5,754 - 93,484 DALYs, yielding net savings in four scenarios, and a cost per DALY averted of $24 - $111 in the four scenarios with net costs. Results were robust in sensitivity analyses. CONCLUSIONS: Eliminating MTCT of syphilis through expanded screening and treatment in ANC is likely to be highly cost-effective by WHO-defined thresholds in a wide range of settings. Countries with high prevalence, low current service coverage, and high healthcare cost would benefit most. Future analyses can be tailored to countries using local epidemiologic and programmatic data.

Hospitalization cost of congenital syphilis diagnosis from insurance claims data in the United States.

We analyzed medical insurance claims data (2005-2009) to determine the hospitalization costs of newborns with congenital syphilis (CS) diagnoses. We found 44 admission claims with CS diagnosis. The excess cost per case of CS (in 2009 US dollars) was estimated at $9969 (95% confidence interval, $5702-$16,769).

Economic and programmatic aspects of congenital syphilis prevention.

A review of the economic and programmatic aspects of congenital syphilis was conducted and recommendations made for improvement of its prevention. Congenital syphilis is a preventable disease and the tools to prevent it have been available for decades. In both industrialized and developing countries, but particularly the latter, the prevention of congenital syphilis by antenatal screening is cost-effective and may be cost-saving. Yet, globally, there are probably >500 000 fetal deaths a year from congenital syphilis, a figure rivalling that from mother-to-child transmission of human immunodeficiency virus (HIV), which receives far greater attention. The reasons that congenital syphilis persists vary, with international and national under-appreciation of the burden of congenital syphilis and insufficient political will to provide effective antenatal screening programmes probably being the main reasons. All causes are amenable to effective intervention programmes. The prevention of congenital syphilis should be a global priority; international agencies and national programmes should be committed to improving antenatal care (ANC) services including syphilis detection and prevention.

Treatment of infants with reactive syphilis serology, New Jersey: 1992 to 1996.

BACKGROUND AND RATIONALE: Diagnosis of congenital syphilis is problematic: infants with congenital syphilis are often asymptomatic, and signs in symptomatic infants are frequently subtle and nonspecific. Furthermore, there are no readily available diagnostic tests that provide a definitive diagnosis. Previously, the diagnosis of congenital syphilis was based on a complex set of clinical and laboratory criteria, and only infants with clinically apparent illness or laboratory findings indicating congenital syphilis were classified as cases and reported to health departments and the Centers for Disease Control and Prevention (CDC). To systematize diagnosis and case-reporting, the CDC developed a standardized surveillance case definition in 1988. This case definition includes symptomatic infants as well as asymptomatic infants of mothers with untreated or inadequately treated syphilis during pregnancy. It is intended to be highly sensitive to better estimate the burden of disease in the community. Treatment guidelines for congenital syphilis are intentionally conservative and err on the side of overtreatment so that all potentially infected infants are treated. The congenital syphilis surveillance case definition is compatible with the American Academy of Pediatrics (AAP) and CDC treatment guidelines; thus, the number of infants identified and reported to state health departments and the CDC should reflect the number of infants treated. Hundreds of infants with reactive serologic tests for syphilis (STS) are reported each year to the New Jersey Department of Health and Senior Services (NJDHSS). The majority of these infants do not meet the case definition for congenital syphilis, and most are treated although treatment guidelines indicate that treatment is not necessary. OBJECTIVE: To determine whether infants with reactive STS in New Jersey are being treated according to the AAP treatment guidelines. METHODS: Medical records of newborns with reactive STS reported to NJDHSS between July 1, 1992, and June 30, 1996, were reviewed to determine status of infection and compliance with the AAP treatment guidelines. The 1995 NJDHSS Uniform Billing and Hospital Discharge Data was used to estimate the mean cost of hospitalization per day for infants with the diagnosis of congenital syphilis. Results. During the study period, 1669 newborns with reactive STS were reported to the NJDHSS Sexually Transmitted Disease Program. Medical record review was completed for 1480 infants (88%). Infants were classified by CDC surveillance criteria as follows: 0 confirmed cases; 515 (35%) presumptive cases; 16 (1%) syphilitic stillbirths; and 949 (64%) cases that did not meet the definition for congenital syphilis. Of the 512 presumptive cases that survived the immediate perinatal period, 478 (93%) were treated with antibiotics and 459 (90%) were treated according to the AAP treatment guidelines. Only 27 infants (6%) were treated with a single intramuscular dose of benzathine penicillin. Thirty-four infants (7%) were not treated; instead, their physicians chose to follow them clinically and serologically. All of those treated were asymptomatic, and most were born to mothers with a history of adequate treatment before or during pregnancy, but who were without serologic follow-up. Of the 949 infants that did not meet the case definition, 329 infants (35%) were not treated and 620 (65%) were treated with antibiotics. The 508 (82%) infants treated with antibiotics were treated with intravenous or intramuscular antibiotics for 10 days; only 62 (10%) were treated with a singular intramuscular dose of benzathine penicillin. According to NJDHSS Uniform Billing Hospital Discharge Data, 267 infants weighing >/= 2500 g were discharged with a diagnosis of congenital syphilis in 1995. The median number of hospital days for these infants was 10, and the mean cost of hospitalization per day was $1010. Sources of payment of hospital charges for most infants were public in

The hospital cost of congenital syphilis.

OBJECTIVE: To determine the hospital cost of caring for newborn infants with congenital syphilis. STUDY POPULATION: All live-born singleton neonates with birth weight greater than 500 gm at an inner-city municipal hospital in New York City in 1989. METHODS: We compared the characteristics of 114 infants with case-compatible congenital syphilis with those of 2906 infants without syphilis. Cost estimates were based on New York State newborn diagnosis-related groups (DRG) reimbursements adjusted for length of stay, birth weight, preterm delivery, and selected maternal risk factors, including infection with the human immunodeficiency virus, cocaine use during pregnancy, and history of injected drug use. RESULTS: For infants with congenital syphilis, the unadjusted mean cost ($11,031) and the median cost ($4961) were more than three times larger than those for infants without syphilis (p < 0.01). After adjustment, congenital syphilis was associated with an additional length of hospitalization of 7 1/2 days and an additional cost of $4690 (both p < 0.01) above mean study population values (7.13 days, $3473). CONCLUSIONS: Based on the number of reported cases (1991 to 1994), the average annual national cost of treating infants with congenital syphilis is approximately $18.4 million (1995 dollars). This estimate provides a benchmark to assess the cost-effectiveness of strategies to prevent, diagnose, and treat the disease.

The cost of a preventable disease: estimated U.S. national medical expenditures for congenital syphilis, 1990.

Reported cases of congenital syphilis have increased rapidly in recent years. The purpose of this study was to estimate first-year medical care expenditures among 1990 incident cases of infants diagnosed with congenital syphilis. The authors used a synthetic estimation model to calculate expenditures for congenital syphilis as the number of treated cases multiplied by cost per case. The number of cases was derived from surveillance data adjusted for underreporting and presumptive (false-positive) treatment. Cost per case was based on expected hospital and physician charges applied to case treatment protocols appropriate to case severity. Base-case estimated first-year medical expenditure for 1990 treated cases (N = 4,400) in 1990 was +12.5 million. In sensitivity analysis, estimates ranged from +6.2 million to +47 million. Substantial reduction in congenital syphilis treatment costs could be achieved through targeted public health interventions consisting of prenatal maternal screening and contact tracing of males testing positive for syphilis. Physicians should be aggressive in presumptive treatment of newborns, since this usually prevents future disability but represents a small portion of total national expenditure for congenital syphilis. More precise data on severe cases resulting in long-term disability are needed to make reliable cost estimates.

Evaluation of congenital syphilis surveillance system--New Jersey, 1993.

To monitor disease burden and trends associated with congenital syphilis (CS), effective prevention programs require a surveillance system that identifies CS cases in an accurate and timely manner. Before 1988, comprehensive CS surveillance was difficult for health departments to conduct because documentation of infection in infants required complex and costly long-term follow-up for up to 1 year after delivery; follow-up often was incomplete, and many infected infants were not identified. To estimate the public health burden of CS more accurately and eliminate long-term follow-up of infants by health department personnel, in 1988 CDC implemented a new CS case definition (1). Rather than relying on documentation of infection in the infant, the new case definition presumes that an infant is infected if it cannot be proven that an infected mother was adequately treated for syphilis before or during pregnancy (2). During 1993-1994, the Sexually Transmitted Disease Prevention and Control Program of the New Jersey Department of Health (NJDOH) evaluated its CS surveillance system to assess the accuracy and completeness of reporting using the new case definition and to determine the personnel costs associated with identifying and classifying CS cases. This report summarizes the results of the evaluation.

Cost-benefit analysis of a prenatal preventive programme against congenital syphilis.

Serologic screening of pregnant women to prevent congenital syphilis has been obligatory in Norway since 1948. Today the incidence of unrecognized, untreated maternal syphilis is approximately 0.2 per 1000 pregnancies. A cost-benefit model is applied to the current prenatal screening programme in Norway. Although may of the benefit parameters are given only an approximate value, or are not valued at all, it was found that the benefit-cost ratio was nearly 2 (1.9), indicating that the economic benefits or savings to the society represent twice the cost of the preventive programme.

PIP: A cost-benefit analysis of Norway's serologic screening program to prevent congenital syphilis is presented. This screening has been obligatory for pregnant women since 1948. The frequency of unrecognized maternal syphilis in Norway is estimated at 0.02%, indicating that 10 pregnancies/year are at risk. If maternal infection is not treated, these pregnancies are assumed to result in 2 uninfected infants, 4 spontaneous abortions or fetal deaths, and 4 congenitally infected infants. 2 of the infected infants will require lifetime institutional care and 2 will need special education or training. The monetary cost of an untreated, undetected syphilis infection in pregnancy encompasses both direct costs (for longterm institutional or medical care, special education and rehabilitation of children with deformities or retardation) and indirect costs (loss of economic productivity attributable to the disease as a result of death or disability). When the cost of education for normal children is subtracted from the cost for the special care and training programs for infected children, a savings of Nkr 932,800 in direct costs results. The difference between the assumed future economic productivity of children with and without the preventive program (indirect cost) is Nkr 455,800. Thus, the total economic benefit resulting from the syphilis screening program is approximately Nkr 1,388,600 for 1 year. The total cost of a 1-year screening program for the detection, treatment, and follow-up of congenital syphilis equals Nkr 719,200, yielding a cost-benefit ratio of 1.9. Even if indirect costs are excluded, the benefit in direct costs exceeds the program costs. Moreover, the cost-benefit ratio in this analysis is considered to be a conservative estimate since a discount rate of 10% was used in calculations of future income and public resources help; the Ministry of Finance has recommended a discount rate of 7%. The net savings to society indicate that the obligatory screenings should continue. In addition to economic benefits, the program provides systematic tracing of asymptomatic cases and their contacts and prevents epidemic outbreaks of syphilis.